{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:23:41Z","timestamp":1783175021400,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107244","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:39:04Z","timestamp":1778283544000},"page":"107244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience"],"prefix":"10.1016","volume":"111","author":[{"given":"Bassem","family":"Yamout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Shatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Inshasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Szolics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Farw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Beriam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghida","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-5609","authenticated-orcid":false,"given":"Maya","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107244_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578164","article-title":"Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers","volume":"382","author":"Adamec","year":"2023","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.msard.2026.107244_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107885","article-title":"A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine","volume":"232","author":"Al-Hashel","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.msard.2026.107244_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2024.108615","article-title":"Deleu D. Real world experience with cladribine tablets in the management of relapsing multiple sclerosis in Qatar","volume":"247","author":"Ca\u00f1ibano","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.msard.2026.107244_bib0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14656566.2013.754012","article-title":"Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis","volume":"14","author":"Comi","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.msard.2026.107244_bib0003","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.msard.2026.107244_bib0022","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001187","article-title":"Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS","volume":"9","author":"de Stefano","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.msard.2026.107244_bib0001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.msard.2026.107244_bib0021","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"5","key":"10.1016\/j.msard.2026.107244_bib0007","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.msard.2026.107244_bib0023","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.msard.2026.107244_bib0002","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to Treat Relapsing Forms of Multiple Sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.msard.2026.107244_bib0014","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40120-021-00243-6","article-title":"Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates","volume":"10","author":"Inshasi","year":"2021","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.msard.2026.107244_bib0015","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40120-023-00497-2","article-title":"Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study","volume":"12","author":"Inshasi","year":"2023","journal-title":"Neurol Ther"},{"issue":"3","key":"10.1016\/j.msard.2026.107244_bib0008","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107244_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.msard.2026.107244_bib0018","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.msard.2026.107244_bib0009","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS: The ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.msard.2026.107244_bib0019","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","article-title":"Halper J. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]","volume":"12","author":"Newsome","year":"2023","journal-title":"Neurol Ther"},{"issue":"10","key":"10.1016\/j.msard.2026.107244_bib0017","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s10072-023-06838-1","article-title":"Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study","volume":"44","author":"Papathanasiou","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.msard.2026.107244_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13","author":"Patti","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.msard.2026.107244_bib0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol Ther"},{"issue":"2","key":"10.1016\/j.msard.2026.107244_bib0028","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107244_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103755","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","volume":"61","author":"Rauma","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.msard.2026.107244_bib0020","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.msard.2026.107244_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.msard.2026.107244_bib0016","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.msard.2026.107244_bib0013","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","article-title":"Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study","volume":"270","author":"Zanetta","year":"2023","journal-title":"J Neurol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:13:39Z","timestamp":1783174419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"alternative-id":["S2211034826002804"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107244","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107244"}}